Form Health

Form Health

Hospitals and Health Care

Boston, Massachusetts 4,161 followers

Form Health is the national leader in science-based obesity care.

About us

Form Health is the national leader in science-based obesity care. Our clinical care model consists of one-on-one, personalized care from a dedicated ABOM-certified physician and a CSOWM-certified Registered Dietitian, who develop individualized treatment plans that address nutrition, physical activity, mindset shifts, and include a prescription for FDA-approved medication, if appropriate. Form Health keeps safety, efficacy, and outcomes at the forefront as we incorporate the latest research and science into our approach. This means we’re always innovating, constantly getting smarter about the science of obesity care, relentlessly focusing on exceptional results, and calling out harmful practices that hold back progress. The result is life-changing outcomes for our patients and meaningful ROI for our enterprise partners. Form Health is in-network with national health plans. Learn more at formhealth.co.

Website
http://formhealth.co
Industry
Hospitals and Health Care
Company size
51-200 employees
Headquarters
Boston, Massachusetts
Type
Privately Held
Founded
2019

Locations

  • Primary

    109 State St

    5th Floore

    Boston, Massachusetts 02109, US

    Get directions

Employees at Form Health

Updates

  • View organization page for Form Health, graphic

    4,161 followers

    Meet Kody Reiser, Form Health Registered Dietitian. Kody enjoys being part of a multidisciplinary team that prioritizes each patient's well-being and delivers best-in-class care. He especially loves the opportunity to help patients establish a healthy relationships with food. Are you passionate about making a difference in people's lives and transforming obesity care? Explore our career opportunities and join our amazing team: https://lnkd.in/dZUp2V6p

  • View organization page for Form Health, graphic

    4,161 followers

    In NYC next week for the Northeast Business Group on Health Pharmacy Benefits Conference? Don't miss Chief Medical Officer, Florencia Halperin on the panel "GLP-1s: Medication evolution, trends in utilization, and what employers should be doing now." Dr. Halperin will share her insights on how employers can provide clinical obesity care that delivers meaningful outcomes and maximizes ROI. Be sure to connect with Jen Cressman during the event to discover how Form Health can help your organization. Not attending but want to learn more? Email us at employers@formhealth.co.

    • No alternative text description for this image
  • View organization page for Form Health, graphic

    4,161 followers

    The rising costs of GLP-1 medications are concerning to many organizations, but it's important to take a broad view. Cardiometabolic conditions like obesity and diabetes along with 200+ weight-related comorbidities are major contributors to healthcare spending. GLP-1s can be a core part of the solution by helping patients achieve sustained weight loss and improved health. At Form Health, medication is just one part of our science-based, comprehensive approach. Is your organization looking for an impactful and cost-effective solution to address the high cost of obesity and metabolic disease? Contact us at employers@formhealth.co to learn how we can help.

    Beyond The Sticker Shock: Why GLP-1s Might Save More Than They Cost

    Beyond The Sticker Shock: Why GLP-1s Might Save More Than They Cost

    social-www.forbes.com

  • View organization page for Form Health, graphic

    4,161 followers

    It's no secret that GLP-1 medications are driving up healthcare costs for many employers, and they're also top of mind for many employees. This creates a unique challenge for benefits leaders who want to offer robust benefits while managing expenses. That's where Form Health can help. At Form Health, obesity medication is just one part of our science-based, comprehensive approach to helping patients achieve weight loss and improved health. Is your organization looking for an impactful and cost-effective solution to address the high cost of obesity and metabolic disease? Contact us at employers@formhealth.co to learn how we can help.

    Workplace insurance could soon be stripped down

    Workplace insurance could soon be stripped down

    axios.com

  • Form Health reposted this

    View profile for Lauren Lemieux, MD, FACP, DABOM, graphic

    Lead Obesity Medicine Physician at Form Health

    Another win for patients with heart failure and overweight/obesity! How so? Using data from the SELECT trial, a new study (1) involving over 4,000 patients with atherosclerotic cardiovascular disease, heart failure and overweight/obesity (BMI 27+) has shown promising results. Compared to those without heart failure, patients with heart failure who were treated with Wegovy (semaglutide) experienced a 28% lower risk of major adverse cardiac events aka MACE (heart attack, stroke, and cardiovascular death) and a 21% reduced risk of the composite heart failure endpoint (cardiovascular death or hospitalization or urgent hospital visit for heart failure). Compared to treatment with placebo, it was also clear that treatment with Wegovy led to better cardiovascular outcomes (see study for full details). Why is there so much hype about Wegovy? Wegovy is a GLP-1 receptor agonist that continues to make headlines with its wide-ranging therapeutic impact. In addition to significant weight loss, studies show it improves glycemic control, reduces risk for cardiovascular disease in patients with established history of atherosclerotic cardiovascular disease (1), and provides numerous cardiovascular benefits in patients with heart failure with preserved ejection fracture and obesity (2, 3), among other benefits. Why is this study important? Currently, Wegovy is FDA-approved for two indications (1) weight loss (and maintenance) and (2) to reduce the risk of MACE in adults with established cardiovascular disease and obesity/overweight. Findings like those described in patients with heart failure can potentially broaden the accessibility of Wegovy. As it stands, many insurance companies (including Medicare) refuse to cover medications FDA-approved for obesity treatment. Meanwhile, they may cover the medication for other indications, such as the newly approved indication for cardiovascular disease risk reduction. Medicare’s decision to cover Wegovy for this indication(4) was a step in the right direction to improving access to care. However, there is still a lot of work to be done. Final thoughts: Last but not least, Wegovy (and other similar medications) are not miracle drugs by themselves! They are to be used in combination with comprehensive lifestyle changes including healthy nutrition, increased physical activities and behaviors to support long-term weight management. They are not appropriate for everyone, and if used should be with the support and supervision of an experienced medical clinician. 1. The Lancet article: https://lnkd.in/g9jQhYqV 2. SELECT Trial:  https://lnkd.in/gQ4Q-Fqf 3. STEP-HFpEF Trial: https://lnkd.in/gd5PfBJP 4. STEP-HFpEF DM Trial: https://lnkd.in/gSE9UwgE 5. Medicare coverage of Wegovy: https://lnkd.in/g2uq8BmG

    Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

    Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

    thelancet.com

  • View organization page for Form Health, graphic

    4,161 followers

    As Dr. Emily Smith MD explains, the initial results from the SURMOUNT-1 trial highlight the significant impact that treating obesity can have on preventing or resolving weight-related comorbidities. Is your organization seeking a partner to help address the high costs of obesity and metabolic diseases? Contact us at employers@formhealth.co to learn how we can help.

    View profile for Emily Smith MD, graphic

    Individualized Medically Supervised Weight Loss

    I am encouraged by the exciting results highlighted in Eli Lilly’s recent press release of data from their three-year SURMOUNT-1 study on tirzepatide, the active ingredient in their weight loss drug Zepbound. The study focused on people with prediabetes, a condition which increases the risk of developing type 2 diabetes, who were overweight or have obesity. Remarkably, those who received weekly injections of tirzepatide saw a 94% reduction in their risk of developing Type 2 diabetes compared to those given a placebo. Participants taking the highest dose of tirzepatide also experienced significant weight loss, losing an average of 22.9% of their body weight over the course of the study. These findings suggest that tirzepatide could be a game-changer in preventing diabetes in addition to treating the disease of obesity, offering hope to millions of people at risk for these conditions. I am hopeful that this will continue to facilitate the expansion of access to and coverage for these life-changing medications to more patients who could benefit.

    Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight | Eli Lilly and Company

    Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight | Eli Lilly and Company

    investor.lilly.com

  • Form Health reposted this

    View profile for Lauren Lemieux, MD, FACP, DABOM, graphic

    Lead Obesity Medicine Physician at Form Health

    I appreciate Evan Richardson's honest take on the motivation behind using compounded medications. These companies will cite "improving health equity" as a reason to provide compounded medications in an attempt to obscure the obvious financial motivation and potentially puts patients at an unnecessary risk for harm. I agree that we need better access to effective anti-obesity medications (to be used under medical supervision with comprehensive lifestyle changes) but not at the risk to patients. Compounded drugs pose a higher risk to patients than FDA-approved drugs because compounded drugs do not undergo FDA premarket review for safety, quality or effectiveness. This article from Bloomberg (see below) has a great example of this very practice: "With brand-name weight-loss drugs costing over $1,000 a month, telehealth providers are luring in customers with lower prices. For $249 a month, Henry Meds offers a membership that includes dissolving tablets* or droplets* of semaglutide. The company also offers subscriptions for injectable drugs for more money....When [Steven Peacock, chief medical officer of Henry Meds was] asked what data Henry Meds has to show their dissolving drugs are as effective as the shots, he didn’t provide any." *There are currently no FDA-approved "dissolving tablets/droplets" of semaglutide. Rybelsus is an FDA-approved oral semaglutide tablet that you swallow (not designed to dissolve on the tongue). Bloomberg: https://lnkd.in/gKKaAVFH FDA: https://lnkd.in/g2gi8jkN

    View organization page for Form Health, graphic

    4,161 followers

    Form Health CEO, Evan Richardson recently spoke with Modern Healthcare about the growing number of telehealth companies offering compounded GLP-1. He says, "This is extremely questionable from a safety perspective, and is a push for them to keep that channel open and keep that line of business open. I think it is quite transparently nothing more than that." At Form Health, patient safety is our top priority. We do not endorse the use of compounded drugs due to significant quality and safety concerns. Form Health providers only prescribe FDA-approved medications, if clinically appropriate. Is your organization looking for an obesity solution that prioritizes patient safety? Contact us at employers@formhealth.co to learn how we can help.

    Telehealth companies are split on compounded GLP-1s

    Telehealth companies are split on compounded GLP-1s

    modernhealthcare.com

  • View organization page for Form Health, graphic

    4,161 followers

    Form Health CEO, Evan Richardson recently spoke with Modern Healthcare about the growing number of telehealth companies offering compounded GLP-1. He says, "This is extremely questionable from a safety perspective, and is a push for them to keep that channel open and keep that line of business open. I think it is quite transparently nothing more than that." At Form Health, patient safety is our top priority. We do not endorse the use of compounded drugs due to significant quality and safety concerns. Form Health providers only prescribe FDA-approved medications, if clinically appropriate. Is your organization looking for an obesity solution that prioritizes patient safety? Contact us at employers@formhealth.co to learn how we can help.

    Telehealth companies are split on compounded GLP-1s

    Telehealth companies are split on compounded GLP-1s

    modernhealthcare.com

  • Form Health reposted this

    View profile for Lauren Lemieux, MD, FACP, DABOM, graphic

    Lead Obesity Medicine Physician at Form Health

    Articles like these highlight how important is to be under close medical supervision while taking weight loss medications. I've seen these medications in combination with comprehensive lifestyle changes and cognitive behavioral therapy lead to dramatic improvement in (and even resolution of) binge eating disorder, and it is life changing for these patients. Nevertheless, it is crucial to be on the lookout for signs of restrictive eating behaviors and intervene sooner rather than later. To learn more about eating disorders and treatment resources, check out National Eating Disorders Association (https://lnkd.in/g23N2Tyq). https://lnkd.in/gdYkbFEN

    Weight loss drugs like Wegovy may trigger eating disorders in some patients, doctors warn

    Weight loss drugs like Wegovy may trigger eating disorders in some patients, doctors warn

    nbcnews.com

Similar pages

Browse jobs

Funding

Form Health 3 total rounds

Last Round

Series B

US$ 38.0M

See more info on crunchbase